LRPAP1 and Alzheimer disease: The major reason for the accumulation of RAP‐RL along the cerebral microvasculature lies in that a key component of the nanostructure, RAP, a peptide derived from RAGE's nature ligand S100P, can specifically bind to RAGE overexpressing on the endothelium of AD cerebral vasculature.[15, 38] Notably, we also evaluated the interaction between RAP‐RL and cerebral blood vessels in brain sections from AD patients, observing the accumulation of RAP‐RL along the vessel walls (Figure S3, Supporting Information).